Level C· Early human research exploring benefitsCase Report / SeriesEurope PMCOpen access

Case Report: Xenogeneic mesenchymal stem cell secretome for the treatment of feline chronic gingivostomatitis

Almendros A., Nekouei O., Moores C., Jesky R., Baiker K., Tse M.

Case Report / Series on Immune Modulation, published in Front Vet Sci (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Front Vet Sci (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40612155
PMCID
PMC12225306
DOI
10.3389/fvets.2025.1603383

Abstract (original English)

This case series describes the treatment of eight cats with mesenchymal stem cell (MSC) secretome, a therapeutic modality never used before for refractory feline chronic gingivostomatitis (FCGS). The cats were free of systemic illness and were not on immunomodulators during treatment. All cats received two to three treatments of MSC secretome through intramucosal injections given 3 months apart. White cell count and globulins, stomatitis disease activity index (SDAI), and histopathology were used pre- and post-treatment to assess the response to treatment. Of the eight selected cases, resolution of clinical signs and significant improvement of lesions were reported in two cats. Six cats did not have a substantial clinical response, and lesions remained mostly unchanged. Six cats had a reduction in globulins, and five cats increased in weight, respectively, after treatment. SDAI decreased in all the cats treated. The two cats that had resolution of clinical signs had the most significant decrease in serum globulins and SDAI, and both increased in weight. No adverse effects or chemistry and hematological abnormalities directly associated with the use of MSC secretome were observed in any of the cats, suggesting human-derived MSC secretome can be safely used in cats. Increases in weight and reductions in SDAI and globulinaemia were observed in a subset of cats after treatment, sug

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research